In line with reports underscoring the importance of Kv1.3 channels in survival of leukemic B cells [28, 55] and various cancer cell lines [54], our data provide initial evidence that Kv1.3 channels are druggable targets in chemotherapy of T-ALL and AML. This evidence concerns the gene KCNA3 and acute myeloid leukemia.